Seven-day triple therapy is a better choice for Helicobacter pylori eradication in regions with low antibiotic resistance

Table 1 Demographic data of patients in this study

	Patients (n = 1106)	Follow-up patients (n = 920)
Gender
Male	572	486
Female	534	434
Age
≤ 10	1	1
11-20	3	1
21-30	54	51
31-40	146	127
41-50	214	183
51-60	321	281
61-70	314	239
71-80	49	35
81-90	4	2
Endoscopic diagnosis
Superficial gastritis	302	246
Atrophic gastritis	24	22
Reflux gastritis	35	31
Erosive gastritis	597	504
Gastric ulcer	28	22
Ulcer of gastric fundus	1	1
Ulcer of gastric antrum	8	8
Ulcer of gastric angle	6	4
Duodenal ulcer	72	57
Gastroduodenal ulcer	30	23
Other	3	2

Table 2 Antimicrobial susceptibility testing in Helicobacter pylori strains n (%)

Antibiotic	Resistant isolates of each group in follow-up patients
	Total (n = 920)	A group (n = 366)	B group (n = 346)	C group (n = 208)
CLR	82 (8.91)	29 (7.9)	30 (8.67)	23 (11.06)
LVX	136 (14.78)	54 (14.75)	50 (14.45)	32 (15.38)
MTZ	881 (95.76)	354 (96.72)	330 (95.38)	197 (94.71)
MTZ + CLR	79 (8.59)	28 (7.65)	29 (8.38)	22 (10.58)
MTZ + LVX	131 (14.24)	52 (14.21)	49 (14.16)	30 (14.42)
CLR + LVX	39 (4.24)	9 (2.50)	13 (3.76)	17 (8.17)
MTZ + CLR + LVX	37 (4.02)	9 (2.50)	12 (3.47)	16 (7.69)

CLR: Clarithromycin; LVX: Levofloxacin; MTZ: Metronidazole; AMX: Amoxicillin.

Table 3 Eradication rates of groups A, B and C in antibiotics resistant and susceptible patients n (%)

	Group A	Group B	Group C
CLR resistance	23 (79.31)	28 (93.33)	21 (91.30)
CLR susceptibility	308 (91.39)	285 (90.19)	168 (90.81)
LVX resistance	51 (94.44)	46 (92.00)	30 (93.75)
LVX susceptibility	281 (90.01)	267 (90.20)	159 (90.34)